View Bridgewest Group Investment portfolio companies

Drug CRDMO

Third largest global contract research, development and manufacturing organization (CRDMO) that provides biopharmaceutical partners with fully integrated services to support drug discovery, development and manufacturing for both drug substance and drug product.

2005 year invested
Dr. Armin Spura, CEO ›

Biologics CDMO

Global, multi-product biologics contract development and manufacturing organization (CDMO), with end-to-end drug substance and sterile fill-finish manufacturing services, spanning both large and small molecules, with expertise in microbial, pDNA, and RNA.

2020 year invested
Mark W. Womack, CEO ›

Sterile Injectable Drug Products

Global supplier of sterile injectable pharmaceutical drugs spanning high potency, blow fill seal and multi format vials.

2023 year invested
Mark Crotty, Interim CEO ›

Conditionally Active Biologics

Global clinical-stage biotechnology company utilizing proprietary Conditionally Active Biologics (CAB) technology to develop novel monoclonal antibody and other protein therapeutic product candidates with more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing than traditional antibodies.

2010 year invested
Dr. Jay Short, CEO ›

Biopharmaceutical Company

Preclinical biopharmaceutical company developing single-target and combo-therapeutic CAR-T therapies that are fine-tuned to comprehensively target a patient's solid tumors and their microenvironments.

2019 year invested
Dr. Laurence Cooper,
Executive Chairman ›

Preclinical Biopharmaceutical

Preclinical biopharmaceutical development company focusing on best-in-class small and large molecule therapeutics, and cell-therapy, to address the unmet medical needs of patients.

2015 year invested

Automated Manufacturing of CAR-T cell

BioOra Limited is a partnership between Bridgewest Ventures and the Malaghan Institute of Medical Research. Through automated manufacturing of CAR-T cell immunotherapy, BioOra can deliver life-saving immunotherapies at substantially less cost.

2021 year invested
John Robson,
Managing Director ›

Bionanorod-based Immunodiagnostics

Pioneers of the biological scalable nanorod technology platform with applications in immunodiagnostics.

2022 year invested
Paul Smith, CEO ›

Biotechnology Company

A biotechnology company leveraging patented 3D printed chromatography columns for separating and purifying biological molecules from a fluid mixture. Serving the medicinal therapeutics industry, enabling purification of DNA, RNA, viruses, and antibodies used in vaccines and cell and gene therapies.

2022 year invested
Dr. Sean Feast, CEO ›

Surgical Tools

A medical technology company with a novel revascularization device to help plastic surgeons restore form and function for patients who are left disfigured from disease and deformity.

2022 year invested
Dr. Nandoun Abeysekera, CEO ›

Ophthalmic Therapeutics

TheiaNova is developing transformative, new, non-invasive therapies for patients with vision impairment due to ectatic vision disorders.

2022 year invested
Dr. Carissa Fonseca, CEO ›

Skin Cancer Screening Tool

Luminoma is pioneering a non-invasive skin cancer screening tool. By detecting molecular changes in cells, Luminoma delivers rapid and accurate diagnosis, reducing patient stress and healthcare system burden.

2023 year invested
Maher Khaled, CEO, Founder ›

Our Investment Portfolio